shortage list tirzepatide Mounjaro and Zepbound Are No Longer in Shortage, F.D.A. Says FDA says that the GLP-1

A thorough evaluation is essential to determine suitability and minimize potential risks

In SURMOUNT-1 (N=2,539), participants receiving 15 mg tirzepatide lost a mean of 20.9% of body weight at 72 weeks versus 3.1% with placebo (P 5% weight loss | | Libido / desire | "Has your interest in sexual activity changed since starting?" | Sudden drop coinciding with dose increase | | Body image | "Do you feel differently about your body in intimate situations?" | Persistent negative self-perception despite weight loss | | Relationship dynamics | "Has your partner expressed concern about your eating or mood?" | Active relationship conflict around food behaviors | Nausea, Food Avoidance, and the Shared Meal Problem Thirty-one percent of patients on tirzepatide 15 mg reported nausea during the SURMOUNT-1 trial, with rates highest in the first 12 weeks of titration

Strive for at least 150 minutes of exercise per week, then add strength training sessions

Br J Pharmacol 2022;179(4):557570